Scholar Rock Holding (FRA:2QK) Research & Development: €181.97 Mil (TTM As of Mar. 2026)


FRA:2QK Scholar Rock Holding Corp FRA:2QK
26 GF Score
Price €46.85
! 5 Warning Signs
View Full Analysis

What is Scholar Rock Holding Research & Development?

Scholar Rock Holding FRA:2QK +2.49% 26 Research & Development is €181.97 Mil as of Mar. 2026. GuruFocus rates FRA:2QK with a GF Score™ of 26/100. The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Scholar Rock Holding's Research & Development for the three months ended in Mar. 2026 was €44.82 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €181.97 Mil.

Scholar Rock Holding  (FRA:2QK) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Scholar Rock Holding Research & Development Related Terms

Scholar Rock Holding Research & Development Historical Data

* Premium members only.

The historical data trend for Scholar Rock Holding's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scholar Rock Holding Research & Development Chart

Scholar Rock Holding Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 95.99 117.48 111.78 176.25 178.01

Scholar Rock Holding Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 45.03 54.10 43.01 40.03 44.82
FRA:2QK
26GF Score
Scholar Rock Holding Corp FRA:2QK
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Scholar Rock Holding Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €181.97 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €181.97 Mil mean?
Scholar Rock Holding (FRA:2QK) has a Research & Development of €181.97 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Scholar Rock Holding and its competitors.
Is Scholar Rock Holding's Research & Development too high?
Scholar Rock Holding's current Research & Development is €181.97 Mil. Overall, Scholar Rock Holding has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Scholar Rock Holding's Research & Development compare to COGT and TGTX?
Scholar Rock Holding's Research & Development of €181.97 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Scholar Rock Holding and its competitors. Scholar Rock Holding's current Research & Development is €181.97 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scholar Rock Holding stock overvalued right now?
Scholar Rock Holding (FRA:2QK) has a current Research & Development of €181.97 Mil. The current Research & Development is €181.97 Mil. Scholar Rock Holding's overall GF Score™ is 26/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Scholar Rock Holding (FRA:2QK), the current Research & Development is €181.97 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Scholar Rock Holding Business Description

Other Exchanges SRRK:USA2QK:Germany
Address 301 Binney Street, 3rd Floor, Cambridge, MA, USA, 02142
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
26GF Score

Get the complete analysis for FRA:2QK

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€46.85
Price